ARS Pharmaceuticals (SPRY) Accounts Payables (2020 - 2026)

ARS Pharmaceuticals has reported Accounts Payables for 7 years, with the latest figure at $48.3 million in Q1 2026.

• Quarterly Accounts Payables rose 78.69% year-over-year to $48.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.3 million (up 78.69% YoY) and the FY2025 annual result came in at $37.9 million, up 66.14% from the prior year.
• Accounts Payables improved to $48.3 million in Q1 2026 per SPRY's latest filing, from $37.9 million in the prior quarter.
• Over five years, Accounts Payables peaked at $49.8 million in Q3 2025 and troughed at $126000.0 in Q3 2022.
• A 5-year average of $17.6 million and a median of $9.8 million in 2023 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables plunged 92.67% in 2022, then surged 8586.51% in 2023.
• Over 5 years, Accounts Payables stood at $4.9 million in 2022, then slumped by 56.32% to $2.2 million in 2023, then jumped by 960.4% to $22.8 million in 2024, then jumped by 66.14% to $37.9 million in 2025, then gained by 27.18% to $48.3 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $48.3 million, $37.9 million, and $49.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.